Ligand Pharmaceuticals (LGND) Tax Provisions (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of Tax Provisions data on file, last reported at -$10.9 million in Q1 2026.

• For the quarter ending Q1 2026, Tax Provisions fell 41.21% year-over-year to -$10.9 million; the trailing twelve-month figure through Mar 2026 stood at $31.3 million (up 209.95% YoY), and the FY2025 full-year result was $34.5 million, up 426.82% from the prior year.
• Tax Provisions eased to -$10.9 million in Q1 2026, from $12.0 million in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $38.7 million in Q4 2022 to a low of -$13.5 million in Q2 2024.
• A 5-year average of $4.8 million and a median of $881000.0 in 2023 frame the typical range for Tax Provisions.
• Across the five-year window, Tax Provisions slumped 1629.97% in 2024 and jumped 2764.83% in 2025, its largest moves.
• Tracing LGND's Tax Provisions over 5 years: stood at $38.7 million in 2022, then slumped by 102.82% to -$1.1 million in 2023, then tumbled by 643.54% to -$8.1 million in 2024, then soared by 247.88% to $12.0 million in 2025, then slumped by 190.98% to -$10.9 million in 2026.
• Business Quant data shows LGND's Tax Provisions at -$10.9 million in Q1 2026, $12.0 million in Q4 2025, and $23.9 million in Q3 2025.